DECIPHER LABS LIMITED is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 65 | 46 | 36 | 23 | 14 |
| EBITDA (ex other income) | 6 | (11) | (1) | (7) | (3) |
| margin % | 9.2 | (23.4) | (2.7) | (32.0) | (24.1) |
| Owners' profit | 12 | 0 | (2) | (5) | (3) |
| EPS, as reported (₹) | 11.27 | (2.66) | (1.66) | 5.03 | 3.05 |
| ROE % · ROCE % | 49.4 · 41.6 | (4.1) · (15.4) | (7.7) · (4.5) | (22.2) · (27.9) | (37.4) · (44.7) |
| Debt / equity (x) | 0.43 | 0.04 | 0.00 | 0.01 | 0.06 |
| Cash from operations | 8 | (2) | 5 | (10) | (2) |
| Capex | (0) | (1) | (0) | (0) | (0) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7 | 6 | 6 | 4 | 3 | 4 | 3 | 4 |
| Profit before tax | 1 | (1) | (1) | (6) | (3) | 0 | (1) | 0 |
| Net profit | 1 | (1) | (1) | (4) | (3) | 0 | (1) | (0) |
| EPS (₹) | 0.94 | (1.31) | (0.59) | 4.07 | 3.39 | 0.02 | 0.53 | 0.35 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Manufacturing and Trading of Pharmaceutical drugs | 1 | 4.8 |
| Consultancy Services | 13 | 95.2 |
| Total, before eliminations | 14 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · Newspaper advertisement for 30th AGM on September 30, 2026 | compliance | minimal | — | — |
| 8 Sept 2026 · Book Closure and E-Voting Cut-Off Date for 40th AGM on 30 September 2026 | board shareholder meetings | low | — | — |
| 8 Sept 2026 · Decipher Labs files 40th Annual Report, AGM on Sept 30, 2026 | compliance | low | — | — |
| 8 Sept 2026 · Notice of 40th AGM scheduled for 30 September 2026 via video conferencing | board shareholder meetings | low | — | — |
| 5 Sept 2026 · New statutory auditor appointed, independent director resigns | management changes | medium | — | — |
| 5 Sept 2026 · Board outcome: new statutory auditor appointed, independent director resigns | management changes | medium | — | — |
| 13 Aug 2026 · Revised Q1 FY27 results with segment info correction; consolidated loss narrows | results | medium | — | — |
| 13 Aug 2026 · Q1 FY27 Results: Standalone Revenue Falls to Rs 9.81L, Loss at Rs 2.19 Cr | results | high | — | — |
| 13 Aug 2026 · Decipher Labs Q1 FY27 results: revenue dips, consolidated loss narrows | results | high | — | — |
| 6 Aug 2026 · Board meeting on 13 Aug 2026 to consider Q1 FY27 results | results | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 2,47,033 |
| 84.6 |
| 14.74 |
| 63.7 |
| 15.3 |
| 18.8 |
| 8.7 |
| 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 1.4 | 28.9 | 3 of 169 | 99% |
| P/B | 0.7 | 3.3 | 10 of 163 | 94% |
| ROCE | (44.7) | 10.8 | 177 of 183 | 3% |
| ROE | (37.4) | 10.4 | 167 of 171 | 2% |
| Debt / Equity | 0.1 | 0.1 | 75 of 171 | 57% |
| EBITDA margin | 11.1 | 17.5 | 117 of 165 | 29% |
| Revenue growth | 3.0 | 16.3 | 119 of 161 | 26% |
| Profit growth | 91.3 | 30.9 | 38 of 158 | 76% |
| Market cap | 6 | 839 | 180 of 182 | 1% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
